Mukka Proteins Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target

July 8, 2026
Posted by: Kunal Singla
Category: News

Mukka Proteins CMP Rs.23. Q1 FY27E revenue Rs.165-190 Cr. PAT estimate Rs.2-3 Cr. 12-month target Rs.23-26.

Mukka Proteins Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Mukka Proteins shares trading at Rs.23 against a market capitalisation of Rs.713 Cr and a price-to-earnings multiple of Not meaningful. As a FMCG name on the NSE and BSE, Mukka Proteins enters the Mukka Proteins Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.

This Mukka Proteins Q1 Results FY27 preview is built on a trailing-growth framework applied to the company’s Q1 FY26 base of Rs.173 Cr revenue and Rs.2 Cr net profit, using the most recent year-on-year growth signal from Q4 FY26. This Q1 prediction is a Uniresearch trailing-growth projection, not a formal analyst estimate, and should be read alongside the company’s own guidance once released.

Get Free Investment Predictions and Mukka Proteins Research at Univest

Table of Contents

About Mukka Proteins

Mukka Proteins (NSE: MUKKA) operates in the FMCG space and is tracked on Univest under its NSE and BSE listings. Ahead of the Mukka Proteins Q1 Results FY27 print, the company’s most recent reported quarter (Q4 FY26) shows revenue of Rs.396 Cr and net profit of Rs.21 Cr, forming the base against which the Mukka Proteins Q1 Results FY27 estimates in this article are built. This Mukka Proteins Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.

Mukka Proteins Q1 FY27 Estimates

Metric	Q1 FY27E (Range)	Q1 FY26 Actual	YoY Growth
Revenue (Rs. Cr)	165-190	173	+2.6%
Net Profit / PAT (Rs. Cr)	2-3	2	+50.0%
Results Date	July-August 2026 (indicative)
12-Month Target (Uniresearch Estimate)	Rs.23-26

Univest, a SEBI-Registered Investment Advisor, Tracks Mukka Proteins Ahead of Q1 FY27 Results

Key Catalysts to Watch

1. Rural Demand Recovery

Rural demand recovery and price hikes supporting revenue growth for the quarter is one of the primary variables that analysts are tracking ahead of Mukka Proteins’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Mukka Proteins share price target or faces renewed pressure.

2. Input Cost Moderation

Input cost moderation aiding gross margin versus the year-ago period is one of the primary variables that analysts are tracking ahead of Mukka Proteins’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Mukka Proteins share price target or faces renewed pressure.

3. Distribution Expansion

Distribution expansion and new launches widening the portfolio reach is one of the primary variables that analysts are tracking ahead of Mukka Proteins’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Mukka Proteins share price target or faces renewed pressure.

Download the Univest iOS App or Univest Android App to track Mukka Proteins’s live price and Q1 FY27 result updates.

Key Risks to the Mukka Proteins Q1 Results FY27 Outlook

Input cost inflation in key raw materials pressuring gross margin.
Slower rural demand recovery affecting volume growth.
Intensifying competition from regional and unorganised players.

Q4 FY26 Performance Context for the Mukka Proteins Q1 Results FY27 Print

Mukka Proteins closed Q4 FY26 with revenue of Rs.396 Cr and net profit of Rs.21 Cr, a year-on-year revenue change of +2.6% and PAT change of +52.6% versus Q4 FY25. This base underpins the Mukka Proteins Q1 Results FY27 projection used in this preview and should be read alongside the company’s own Mukka Proteins Q1 Results FY27 commentary once reported.

Technical Analysis Ahead of Mukka Proteins Q1 Results FY27

Mukka Proteins shares last traded at Rs.23. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.

Share Price Target Based on the Mukka Proteins Q1 Results FY27 Outlook

3-6 Month Target

Over a 3-6 month horizon, the Mukka Proteins Q1 Results FY27 trailing-growth framework points to a range of Rs.23-24 for Mukka Proteins, contingent on the Mukka Proteins Q1 Results FY27 print matching or beating the trailing growth trend.

12-Month Target

The 12-month target (Uniresearch estimate) tied to this Mukka Proteins Q1 Results FY27 view for Mukka Proteins works out to Rs.23-26, built on the same trailing revenue growth trend and current valuation multiple. Tracking is how Univest research categorises the stock heading into Mukka Proteins Q1 Results FY27, not a formal Buy or Sell call.

FY27-28 Outlook

Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Mukka Proteins Q1 Results FY27 analysis would put Mukka Proteins in a Rs.24-28 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.

What to Watch in the Mukka Proteins Q1 Results FY27 Print

Revenue and PAT versus the Mukka Proteins Q1 Results FY27 estimate range in this preview.
Management commentary on FY27 growth guidance and margin trajectory relevant to the Mukka Proteins Q1 Results FY27 narrative.
Rural demand recovery and price hikes supporting revenue growth for the quarter
Input cost inflation in key raw materials pressuring gross margin

Conclusion on Mukka Proteins Q1 Results FY27

Mukka Proteins enters the Q1 FY27 results season trading at Rs.23, with the 12-month Uniresearch target range of Rs.23-26 reflecting a tracking stance. Investors tracking the Mukka Proteins Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Mukka Proteins Q1 Results FY27

When are Mukka Proteins Q1 FY27 results expected?

Ans. Mukka Proteins’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.

What is the Mukka Proteins Q1 FY27 revenue estimate?

Ans. The Uniresearch trailing-growth estimate for Mukka Proteins’s Q1 FY27 revenue is Rs.165-190 Cr, based on the Q1 FY26 base of Rs.173 Cr.

What is the Mukka Proteins share price target?

Ans. The 12-month Uniresearch estimate for Mukka Proteins share price target is Rs.23-26, based on trailing growth and current valuation multiples.

Is Mukka Proteins a good buy before Q1 FY27 results?

Ans. Mukka Proteins is tracking heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.

What should investors watch in Mukka Proteins’s Q1 FY27 results?

Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and rural demand recovery and price hikes supporting revenue growth for the quarter.

Where can I track Mukka Proteins share price live?

Ans. Mukka Proteins share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.

News

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.